Trials / Completed
CompletedNCT00067561
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects With Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 702 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alosetron |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-01-01
- Completion
- 2005-01-01
- First posted
- 2003-08-25
- Last updated
- 2015-04-16
Locations
178 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT00067561. Inclusion in this directory is not an endorsement.